Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (81-90 of 157) with videos related to

Pageof 16
Sort By:
The Journal of Infectious Diseases|November 26, 2015
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B SubstitutionsEvguenia S Svarovskaia, Edward Gane, Hadas Dvory-Sobol, et al.
JCI Insight|January 26, 2018
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitisRohit Loomba, Yevgeniy Gindin, Zhaoshi Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosisMaribel Rodriguez-Torres, Albrecht Stoehr, Edward J Gane, et al.
Antiviral Therapy|November 16, 2022
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis BJordan J Feld, Eric Lawitz, Tuan Nguyen, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for previously treated chronic HCV genotype 1 infectionBruce R Bacon, Stuart C Gordon, Eric Lawitz, et al.
Gastroenterology|March 16, 2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseasePaul J Pockros, K Rajender Reddy, Parvez S Mantry, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2022
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairmentMark Sulkowski, Laura E Telep, Massimo Colombo, et al.
Hepatology (Baltimore, Md.)|August 13, 2011
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Richard E Nettles, Min Gao, Marc Bifano, et al.
Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.
Pageof 16

Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
The Journal of Infectious Diseases|November 26, 2015
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B SubstitutionsEvguenia S Svarovskaia, Edward Gane, Hadas Dvory-Sobol, et al.
JCI Insight|January 26, 2018
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitisRohit Loomba, Yevgeniy Gindin, Zhaoshi Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosisMaribel Rodriguez-Torres, Albrecht Stoehr, Edward J Gane, et al.
Antiviral Therapy|November 16, 2022
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis BJordan J Feld, Eric Lawitz, Tuan Nguyen, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for previously treated chronic HCV genotype 1 infectionBruce R Bacon, Stuart C Gordon, Eric Lawitz, et al.
Gastroenterology|March 16, 2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseasePaul J Pockros, K Rajender Reddy, Parvez S Mantry, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2022
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairmentMark Sulkowski, Laura E Telep, Massimo Colombo, et al.
Hepatology (Baltimore, Md.)|August 13, 2011
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Richard E Nettles, Min Gao, Marc Bifano, et al.
Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.
Pageof 16